#

+1 (917) 893 7512

  • #
  • #
  • #
#
Best US Lymphedema Market Research Report

The US Lymphedema Market: Size, Trends & Forecasts (2019-2023 Edition)

Publish Date:Oct 2019
No. of Pages:59

Format : Adobe Reader (PDF) Instant delivery

US$ 850.00

The US Lymphedema Market Research Report :

The report entitled “The US Lymphedema Market: Size, Trends & Forecasts (2019-2023 Edition)”, provides analysis of the US lymphedema market, with detailed analysis of market size and growth, number of patients and penetration, number of patients diagnosed, patients by causes and demographics, etc. The report also provides the detailed analysis of the US Pneumatic Compression Device (PCD) market, by value, by device adoption, by average selling price, etc.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US lymphedema market has also been forecasted for the years 2019-2023, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

The major players dominating the US Lymphedema market are Tactile Systems Technology Inc., Bio Compression System, Lympha Press (Mego Afek) and Essity (BSN Medical). The four companies have been profiled in the report providing detailed analysis of their financial information and business strategies.

Company Coverage
Tactile Systems Technology Inc.
Bio Compression System
Lympha Press (Mego Afek)
Essity (BSN Medical)

Executive Summary

Lymphedema refers to the swelling of one or both of a person’s arms or legs. The most common cause of lymphedema is the removal of the lymph nodes as a part of cancer treatment. Lymphedema is caused by a blockage in the lymphatic system of the affected person.

The most common symptoms of lymphedema include swelling in part or all of the arms or legs, feeling of heaviness or tightness, aching, discomfort, recurring infections and hardening and thickening of the skin. There are two types of lymphedema: Primary Lymphedema and Secondary Lymphedema. Primary lymphedema is detected in the children and it is generally the result of an error in the development of the lymphatic system. Secondary lymphedema represents more than 99% of the total cases. It occurs due to the cancer treatment or surgery, resulting in the removal of lymph nodes.

The US Lymphedema market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2019-2023). The market is expected to be driven by various growth enhancing factors such as growing prevalence of breast cancer, increasing obesity, rise in urban population, escalating healthcare expenditure, rising prevalence of arthritis, and surge in the disposable income.

However, the market is not free from challenges that are hindering its growth. Some of the major challenges faced by the market are high cost involved, improvement in cancer treatment, and lack of awareness.


Tags :







1.Executive Summary
2. Introduction

2.1  Lymphedema: An Overview
2.2 Types of Lymphedema
2.3 Treatment of Lymphedema

3. Market Analysis

3.1 The US Lymphedema Market: An Analysis

3.1.1 The US Lymphedema Market by Number of Patients
3.1.2 The US Lymphedema Market by Number of Patients Diagnosed
3.1.3 The US Lymphedema Market by Number of Diagnosed Patients Severity
3.1.4 The US Lymphedema Total Addressable Market (TAM)

3.2The US Lymphedema Market: Patient Analysis

3.2.1 The US Lymphedema Patients by Causes (Cancer, CVI, Surgery, Trauma, Primary lymphedema and Others)
3.2.2 The US Lymphedema Patients by Demographics (Gender (Male, Female), Age Group (0-18 Years, 19-44 Years, 45-64 Years, 65+ Years))

3.3 The US Lymphedema Pneumatic Compression Device (PCD) Market: An Analysis

3.3.1 The US Pneumatic Compression Device (PCD) Market by Case Adoption
3.3.2 The US Pneumatic Compression Device (PCD) Market by Average Selling Price (ASP)
3.3.3 The US Pneumatic Compression Device (PCD) Market by Value
3.4 The US Lymphedema Market: New Product Analysis
3.4.1 The US Lymphedema Market New Product: Ubenimex
3.4.2 The US Lymphedema Market New Product: Lymfactin

4. Market Dynamics

4.1 Growth Driver
4.1.1 Growing Prevalence of Breast Cancer
4.1.2 Increasing Obesity
4.1.3 Rise in Urban Population
4.1.4 Escalating Healthcare Expenditure
4.1.5 Rising Prevalence of Arthritis
4.1.6 Surge in the Disposable Income

4.2 Challenges
4.2.1 High Cost Involved
4.2.2 Improvement in Cancer Treatment
4.2.3 Lack of Awareness

4.3 Market Trends
4.3.1 Advancement in Treatment Options
4.3.2 Growing Popularity of Pneumatic Compression Devices

5.Competitive Landscape

5.1 The US PCD Players by Market Share
5.2 The US PCD Market Players Comparison

6. Company Profiles

6.1 Tactile Systems Technology Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Bio Compression System
6.2.1 Business Overview
6.2.2 Business Strategy

6.3 Lympha Press (Mego Afek)
6.3.1 Business Overview
6.3.2 Business Strategy

6.4 Essity (BSN Medical)
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Figure 1: Type of Lymphedema
Figure 2: Treatment of Lymphedema
Figure 3: The US Lymphedema Market by Number of Patients and Penetration; 2017-2018 (Million, Percentage, %)
Figure 4: The US Lymphedema Market by Number of Patients and Penetration; 2019-2023 (Million, Percentage, %)
Figure 5: The US Lymphedema Market by Number of Patients Diagnosed; 2017-2018 (Million, Percentage, %)
Figure 6: The US Lymphedema Market by Number of Patients Diagnosed; 2019-2023 (Million, Percentage, %)
Figure 7: The US Lymphedema Market by Number of Diagnosed Patients Severity; 2017-2018 (Thousand, Percentage, %)
Figure 8: The US Lymphedema Market by Number of Diagnosed Patients Severity; 2019-2023 (Thousand, Percentage, %)
Figure 9: The US Lymphedema Total Addressable Market (TAM); 2016-2018 (US$ Billion)
Figure 10: The US Lymphedema Total Addressable Market (TAM); 2019-2023 (US$ Billion)
Figure 11: The US Lymphedema Patients by Causes
Figure 12: The US Lymphedema Patients by Gender
Figure 13: The US Lymphedema Patients by Age Group
Figure 14: The US Pneumatic Compression Device (PCD) Market by Case Adoption; 2017-2023 (Percentage, %)
Figure 15: The US Pneumatic Compression Device (PCD) Market by ASP; 2016-2018 (US$)
Figure 16: The US Pneumatic Compression Device (PCD) Market by ASP; 2019-2023 (US$)
Figure 17: The US Pneumatic Compression Device (PCD) Market by Value; 2018-2023 (US$ Million)
Figure 18: Lymfactin Phase Study
Figure 19: The US Estimated Number of New Breast Cancer Cases; 2015-2019 (Thousand)
Figure 20: The US Obesity Rates; 2015-2030 (Percentage, %)
Figure 21: The US Urban Population; 2014-2018 (Million)
Figure 22: The US Healthcare Expenditure; 2012-2024 (US$ Trillion)
Figure 23: The US Arthritis Population; 2010-2040 (Million)
Figure 24: The US Per Capita Disposable Personal Income; 2012-2018 (US$ Trillion)
Figure 25: The US PCD Players by Market Share; 2016-2021 (Percentage, %)
Figure 26: Tactile Systems Technology Inc. Revenue; 2014-2018 (US$ Million)
Figure 27: Tactile Systems Technology Inc. Revenue by Segments; 2018 (Percentage, %)
Figure 28: Essity Net Sales; 2014-2018 (US$ Billion)
Figure 29: Essity Net Sales by Segments; 2018 (Percentage, %)
Figure 30: Essity Net Sales by Region; 2018 (Percentage, %)
Table 1: Lymphedema Classification Scale
Table 2: Ubenimex Milestones – Lymphedema
Table 3: The US PCD Market Players Comparison